Qiagen N.V. (QGEN) – What Are Brokerages Thinking About This Stock?

Shares of Qiagen N.V. (NYSE:QGEN) have earned an average recommendation of “Hold” from the fifteen ratings firms that are presently covering the company, MarketBeat reports. Eleven equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $45.01.

QGEN has been the subject of a number of recent research reports. Citigroup reiterated a “neutral” rating and issued a $52.00 target price (up from $45.00) on shares of Qiagen in a report on Monday. Berenberg Bank set a $45.50 price objective on shares of Qiagen and gave the stock a “hold” rating in a research note on Tuesday, July 14th. Robert W. Baird boosted their price objective on shares of Qiagen from $50.00 to $52.00 and gave the company an “outperform” rating in a research report on Thursday, October 22nd. UBS Group began coverage on shares of Qiagen in a report on Wednesday, September 9th. They issued a “neutral” rating and a $47.00 target price for the company. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and set a $52.00 price target (down from $55.00) on shares of Qiagen in a report on Thursday, October 22nd.

Qiagen Stock Performance

Shares of Qiagen stock opened at $50.20 on Wednesday. The business has a 50-day moving average price of $44.73 and a 200-day moving average price of $42.70. Qiagen has a twelve month low of $32.53 and a twelve month high of $57.81.

Qiagen (NYSE:QGEN) last posted its earnings results on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. The firm had revenue of $535.04 million during the quarter, compared to analysts’ expectations of $527.50 million. During the same quarter in the prior year, the firm posted $0.60 earnings per share. Qiagen’s quarterly revenue was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. Sell-side analysts expect that Qiagen will post 2.44 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of QGEN. Assenagon Asset Management S.A. lifted its position in shares of Qiagen by 1.9% during the third quarter. Assenagon Asset Management S.A. now owns 15,722 shares of the company’s stock worth $691,000 after purchasing an additional 286 shares during the last quarter. Allworth Financial LP increased its stake in Qiagen by 20.8% in the 2nd quarter. Allworth Financial LP now owns 1,841 shares of the company’s stock worth $72,000 after buying an additional 317 shares during the period. EverSource Wealth Advisors LLC increased its stake in Qiagen by 46.8% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,746 shares of the company’s stock worth $110,000 after buying an additional 876 shares during the period. Quadrant Capital Group LLC lifted its holdings in Qiagen by 2.4% during the 3rd quarter. Quadrant Capital Group LLC now owns 42,660 shares of the company’s stock valued at $1,938,000 after buying an additional 1,003 shares in the last quarter. Finally, Hilltop National Bank bought a new stake in Qiagen during the 2nd quarter valued at about $50,000. Institutional investors own 70.00% of the company’s stock.

About Qiagen

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.